FY26 Appendix 4E
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The report indicates a loss from ordinary activities after tax attributable to the owners of the company, along with no dividends declared during the financial period.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/fy26-appendix-4e-8
Lumos Diagnostics Holdings Ltd. on 6ix
Earlier from Lumos Diagnostics
- FY26 Annual Report
- Lumos to Present at 20th Bioshares Biotech Summit
- Lumos Receives FebriDx Order from PHASE Scientific
- Lumos Secures Distribution for FebriDx in Romania
- Change of Director's Interest Notice - DW
Later from Lumos Diagnostics
- FY26 Full Year Results Announcement
- Appendix 4G and Corporate Governance Statement
- Application for quotation of securities - LDX
- Section 708A Cleansing Statement
- FebriDx Commercial Traction Continues Across US Accounts
Follow Lumos Diagnostics into a list and get an email when it puts out news.
Follow Lumos Diagnostics